Isomeric separation and quantitation of di-(2-ethylhexyl) trimellitates and mono-(2-ethylhexyl) trimellitates in blood by LC-MS/MS.

A new and fast HPLC-method for the simultaneous determination of tri-(2-ethylhexyl) trimellitate (TOTM or TEHTM), its diesters 2,4-di-(2-ethylhexyl) trimellitate (2,4-DEHTM), 1,4-di-(2-ethylhexyl) trimellitate (1,4-DEHTM), 1,2-di-(2-ethylhexyl) trimellitate (1,2-DEHTM) and monoesters 1-mono-(2-ethylhexyl) trimellitate (1-MEHTM), 2-mono-(2-ethylhexyl) trimellitate (2-MEHTM) and 4-mono-(2-ethylhexyl) trimellitate (4-MEHTM) together with di-(2-ethylhexyl) phthalate (DEHP) and its primary metabolite mono-(2-ethylhexyl) phthalate (MEHP) in blood was developed and validated. The analytes are extracted from blood using liquid-liquid extraction and are chromatographically separated by reversed-phase HPLC using core shell material. Quantitative assessment was performed by ESI-tandem mass spectrometry in negative ionization mode using stable isotope dilution. In less than 30min six postulated primary metabolites of TOTM along with the DEHP metabolite MEHP can be selectively and sensitively quantified. Additionally, the method enables the determination of the parent plasticizers TOTM and DEHP. The detection limits in blood were found to range between 0.7-5.5μg/L for all TOTM analytes. Precision and repeatability of the method were proven by relative standard deviations between 0.9% and 8.7%. TOTM, an alternative plasticizer to DEHP, is already increasingly used for medical devices. Nevertheless, data about the human metabolism of TOTM are still limited. The presented method is the first one enabling the simultaneous determination of the parent plasticizers TOTM and DEHP together with their primary degradation products (DEHTM, MEHTM, MEHP) and can thus be applied manifold including the investigation of the human metabolism of TOTM.